Hypertension and microalbuminuria: The new detrimental duo

Blood Pressure

Volumn 13, Issue 4, 2004, Pages 198-211

  Verdecchia, Paolo ^a   Reboldi, Gian Paolo ^b  

^a Ospedale Silvestrini   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Albumin excretion; Cardiovascular risk; Diabetes; Essential hypertension; Microalbuminuria; Target organ damage

Indexed keywords

ALBUMIN; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LIPID; LISINOPRIL; PLACEBO; VALSARTAN;

AGE; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CREATININE URINE LEVEL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MECHANISM; ETHNOLOGY; EVIDENCE BASED MEDICINE; GENDER; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY INJURY; LONGITUDINAL STUDY; MICROALBUMINURIA; OBESITY; PRIORITY JOURNAL; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; URINE LEVEL;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; KIDNEY DISEASES; MODELS, BIOLOGICAL; PROGNOSIS; RISK FACTORS;

EID: 4544354255     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050410016456     Document Type: Review

References (110)

1. Rowe DJF, Dawnay A, Watts GF. Microalbuminuria in diabetes mellitus: Review and recommendations for the measurement of albumin in urine. Ann Clin Biochem 1990; 27: 297-306.
2. American Diabetes Association. Nephropathy in diabetes. Diabetes Care 2004; 27: S79-83.
3. Mogensen CE. Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes. J Int Med 2003; 254: 45-66.
4. Redon J, Williams B. Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002; 20: 353-5.
5. Remuzzi A, Viberti GC, Ruggenenti P, Battaglia C, Pagni R, Remuzzi G. Glomerular response to hyperglycemia in human diabetic nephropathy. Am J Physiol 1990; 259: F545-52.
6. Torres Rosa T, Palatini P. Clinical value of microalbuminuria in hypertension. J Hypertens 2000; 18: 645-654.
7. Lloyd DR, Hindle EJ, Marples J, Gatt JA. Urinary albumin in immunoturbidimetry. Ann Clin Biochem 1987; 24: 209-12.
8. Stamp RJ. Measurement of albumin in urine by end-point immunonephelometry. Ann Clin Biochem 1988; 25: 442-445.
9. Gerber LM, Johnston K, Alderman MH. Assessment of a new dipstick test in screening for microalbuminuria in patients with hypertension. Am J Hypertens 1998; 11: 1321-27.
10. Mogensen CE, et al. Multicenter evaluation of the Micral-Test II test strip, an immunologic rapid test for the detection of microalbuminuria. Diabetes Care 1997; 20: 1642-6.
11. Pedrinelli R, Dell'Omo G, Di Bello V, Pontremoli R, Mariani M. Microalbuminuria, an integrated marker of cardiovascular risk in essential hypertension. J Hum Hypertens 2002; 16: 79-89.
12. Jensen JS, et al. Detecting microalbuminuria by urinary albumin/creatinine concentration ratio. Nephrol Dial Transplant 1997; 12 Suppl 2: 6-9.
13. Parving HH, Jensen HAE, Mogensen CE, Evrin PE. Increased urinary albumin excretion rate in benign essential hypertension. Lancet 1974; 1: 1190-2.
14. Jensen JS, et al. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11: 727-32.
15. Palatini P, et al. Target-organ damage in stage I hypertensive subjects with white coat and sustained hypertension: results from the HARVEST study. Hypertension 1998; 31: 57-63.
16. Pontremoli R, Sofia A, Ravera M, et al. Prevalence and clinical correlates of microalbuminuria in essential hypertension: the MAGIC Study. Microalbuminuria: A Genoa Investigation on Complications. Hypertension 1997; 30: 1135-43.
17. Horner D, Fliser DD, Klimm HP, Ritz E. Albuminuria in normotensive and hypertensive individuals attending offices of general practitioners. J Hypertens 1996; 14: 655-60.
18. Hoegholm A, Kristensen KS, Bang LE, Nielsen JW. White coat hypertension and target organ involvement: the impact of different cut-off levels on albuminuria and left ventricular mass and geometry. J Hum Hypertens 1998; 12: 433-9.
19. Summerson JH, Bell RA, Konen JC. Racial differences in the prevalence of microalbuminuria in hypertension. Am J Kidney Dis 1995; 26: 577-9.
20. Redon J, et al. Ambulatory blood pressure and microalbuminuria in essential hypertension: role of circadian variability. J Hypertens 1994; 12: 947-53.
21. Agewall S, et al. Microalbuminuria in treated men at high risk of coronary disease. J Hypertens 1993; 11: 461-9.
22. Cerasola G, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 14: 915-20.
23. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223-8.
24. Mimran A, Ribstein J, Du Cailar G, Halimi JM. Albuminuria in normals and essential hypertension. J Diab Comp 1994; 8: 150-6.
25. Pedrinelli R, et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35: 48-54.
26. Bigazzi R, Bianchi S, Baldari D, Campese VM. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-33.
27. Calviňo J, et al. Atherosclerosis profile and microalbuminuria in essential hypertension. Am J Kidney Dis 1999; 34: 996-1001.
28. Gatzka CD, et al. Left ventricular mass and microalbuminuria: relation to ambulatory blood pressure. Hypertension Diagnostic Service Investigators. Clin Exp Pharmacol Physiol 1999; 26: 514-16.
29. Tsioufis CP, et al. Microalbuminuria is associated with abnormal thoracic aortic mechanics in essential hypertension. Am J Cardiol 2000; 86: 797-801.
30. Palatini P, Graniero GR, Mormino P, et al. Prevalence and clinical correlates of microalbuminuria in Stage I hypertension. Results from the Hypertension and Ambulatory recording Venetia Study (HARVEST Study). Am J Hypertens 1996; 9: 334-41.
31. Mimran A, Ribstein J, Du Cailar G, Halimi JM. Albuminuria in normals and essential hypertension. J Diab Comp 1994; 8: 150-6.
32. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 31: 1213-20.
33. Cirillo M, et al. Pulse pressure and isolated systolic hypertension: association with microalbuminuria. The GUBBIO Study Collaborative Research Group. Kidney Int 2000; 58: 1211-18.
34. Pedrinelli R, et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000; 35: 48-54.
35. Tsioufis CP, et al. Microalbuminuria is associated with abnormal thoracic aortic mechanics in essential hypertension. Am J Cardiol 2000; 86: 797-801.
36. Christensen CK. Rapidly reversible albumin and beta2-microglobulin hyperexcretion in recent severe essential hypertension. J Hypertens 1983; 1: 45-51.
37. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles - with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229-44.
38. Pedrinelli R. Microalbuminuria in hypertension. Nephron 1996; 73: 499-505.
39. Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese VM. Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens 1994; 7: 23-9.
40. Denker PS, Pollok VE. Fasting serum insulin levels in essential hypertension: a meta analysis. Arch Intern Med 1992; 152: 1649-51.
41. Ferranini E, Buzzigoli G, Bonadonna R, et al. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-7.
42. Bianchi S, Bigazzi R, Valtriani C, et al. Elevated serum insulin levels in patients with essential hypertension and microalbuminuria. Hypertension 1994; 23: 681-7.
43. Bianchi S, Bigazzi R, Quinones Galvan A, et al. Insulin resistance in microalbuminuric hypertension. Sites and mechanisms. Hypertension 1995; 26: 789-95.
44. Redon J, Miralles A, Pascual JM, Baldo' E, Robles RG, Carmena R. Hyperinsulinemia as a determinant of microalbuminuria in essential hypertension. J Hypertens 1997; 15: 79-86.
45. Agewall S, Fagerberg B, Attvall S, et al. Microalbuminuria, insulin sensitivity and hemostatic factors in non diabetic treated hypertensive men. J Int Med 1995; 237: 195-203.
46. Ribstein J, du Cailar G, Mimran A. Combined renal effects of overweight and hypertension. Hypertension 1995; 26: 610-15.
47. Pedrinelli R, Dell'Omo G, Giampietro O, et al. Dissociation between albuminuria and insulinemia in hypertensive and atherosclerotic men. J Hum Hypertens 1999; 13: 129-34.
48. Grandi AM, Santillo R, Zanzi P, et al. Microalbuminuria in never-treated hypertensives: lack of relationship to hyperinsulinemia and genetic predisposition to hypertension. Am J Hypertens 2000; 13: 353-8.
49. Pedrinelli R, Dell'Omo G, Penno G, et al. Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. J Hypertens 2003; 21: 1163-9.
50. Hilsted J, Christensen NJ. Dual effect of insulin on plasma volume and transcapillary albumin transport. Diabetologia 1992; 35: 99-103.
51. Mogensen CE, Christensen NJ, Gundersen HJ. The acute effect of insulin on heart rate, blood pressure, plasma noradrenaline and urinary albumin excretion. The role of changes in blood glucose. Diabetologia 1980; 18: 453-7.
52. Baldoncini R, et al. High plasma renin activity is combined with elevated urinary albumin excretion in essential hypertension. Kidney Int 1999; 56: 1499-504.
53. Pontremoli R, et al. The deletion polymorphism of the angiotensin I-converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996; 7: 2550-8.
54. Kario K, et al. Hypertensive nephropathy and the gene for angiotensin-converting enzyme. Arterioscler Thromb Vasc Biol 1997; 17: 252-6.
55. Cirillo M, Senigalliesi L, Laurenzi M, et al. Microalbuminuria in nondiabetic adults: relation of blood pressure, body mass index, plasma cholesterol levels, and smoking: The Gubbio Population Study. Arch Intern Med 1998; 158: 1933-9.
56. Campese VM, Bianchi S, Bigazzi R. Association between hyperlipidemia and microalbuminuria in essential hypertension. Kidney Int 1999; 71: S10-13.
57. Cerasola G, et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertension. J Hypertens 1996; 14: 915-20.
58. Pontremoli R, et al. Microalbuminuria is an early marker of target organ damage in essential hypertension. Am J Hypertens 1998; 11: 430-8.
59. Nilsson T, et al. The relations of microalbuminuria to ambulatory blood pressure and myocardial wall thickness in a population. J Intern Med 1998; 244: 55-9.
60. Nishikimi T, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22-30.
61. Mc Murray J, et al. The effect of atrial natriuretic factor on urinary albumin and beta 2-microglobulin excretion in man. J Hypertens 1988; 6: 783-6.
62. Bigazzi R, Bianchi S, Nenci R, Baldari D, Baldari G, Campese VM. Increased thickness of the carotid artery in patients with essential hypertension and microalbuminuria. J Hum Hypertens 1995; 9: 827-33.
63. Leoncini G, Viazzi F, Parodi D, et al. Mild renal dysfunction and subclinical cardiovascular damage in primary hypertension. Hypertension 2003; 42: 14-18.
64. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157: 1413-8.
65. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988; 2: 530-3.
66. Ljungman S, Wikstrand J, Hartford M, Berglund G. Urinary albumin excretion - a predictor of risk of cardiovascular disease. A prospective 10-year follow-up of middle-aged nondiabetic normal and hypertensive men. Am J Hypertens 1996; 9: 770-8.
67. Agewall S, Wikstrand J, Ljungman S, Fagerberg B. Usefulness of microalbuminuria in predicting cardiovascular mortality in treated hypertensive men with and without diabetes mellitus. Am J Cardiol 1997; 80: 164-9.
68. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27: 2033-9.
69. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19: 1992-7.
70. Jager A, Kostense PJ, Ruhe HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arteriosc Thromb Vasc Biol 1999; 19: 617-24.
71. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.
72. Hillege HL, Fidler V, Diercks GF, et al. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106: 1777-1782.
73. Gerstein HC, Mann JF, Yi Q, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-6.
74. Roest M, Banga JD, Janssen WM, et al. Excessive urinary albumin levels are associated with future cardiovascular mortality in postmenopausal women. Circulation 2001; 103: 3057-61.
75. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139: 901-6.
76. Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 2001; 104: 1985-91.
77. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992; 340: 319-23.
78. Pedrinelli R, Giampietro O, Carmassi F, et al. Microalbuminuria and endothelial dysfunction in essential hypertension. Lancet 1994; 344: 14-8.
79. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1989; 32: 219-26.
80. Jensen JS, Borch-Johnsen K, Jensen G, et al. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci 1995; 88: 629-33.
81. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation 2001; 103: 1869-74.
82. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Endothelial dysfunction in hypertension. J Cardiovasc Pharmacol 2001; 38 Suppl 2: S11-4.
83. Hoogeveen EK, Kostense PJ, Jager A, et al. Serum homocysteine level and protein intake are related to risk of microalbuminuria: the Hoorn Study. Kidney Int 1998; 54: 203-9.
84. Agewall S, Lindstedt G, Fagerberg B. Independent relationship between microalbuminuria and plasminogen activator inhibitor-1 activity (PAI-1) activity in clinically healthy 58-year-old men. Atherosclerosis 2001; 157: 197-202.
85. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384-94.
86. Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33: 1004-10.
87. Ismail N, Becker B, Strzelczyk P, Ritz E. Renal disease and hypertension in non-insulin-dependent diabetes mellitus. Kidney Int 1999; 55: 1-28.
88. Mathiesen ER, Ronn B, Jensen T, et al. Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 1990; 39: 245-9.
89. Mogensen CE, Hansen KW, Pedersen MM, Christensen CK. Renal factors influencing blood pressure threshold and choice of treatment for hypertension in IDDM. Diabetes Care 1991; 14 Suppl 4: 13-26.
90. Redon J, Rovira E, Miralles A, Julve R, Pascual JM. Factors related to the occurrence of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2002; 39: 794-8.
91. Erley CM, Haefele U, Heyne N, Braun N, Risler T. Microalbuminuria in essential hypertension. Reduction by different antihypertensive drugs. Hypertension 1993; 21: 810-15.
92. Agrawal B, Wolf K, Berger A, Luft FC. Effect of antihypertensive treatment on qualitative estimates of microalbuminuria. J Hum Hypertens 1996; 10: 551-5.
93. Ruilope LM, Alcazar JM, Hernandez E, Praga M, Lahera V, Rodicio JL. Long-term influences of antihypertensive therapy on microalbuminuria in essential hypertension. Kidney Int Suppl 1994; 45: S171-3.
94. Agodoa LY, Appel L, Bakris GL, et al. African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis. JAMA 2001; 285: 2719-28.
95. Monster TB, Janssen WM, de Jong PE, de Jong-van den Berg LT PREVEND Study Group. The impact of antihypertensive drug group on urinary albumin excretion in a non-diabetic population. Br J Clin Pharm 2002; 53: 31-6.
96. Garg J, Bakris GL. Angiotensin converting enzyme inhibitors or angiotensin receptor blockers in nephropathy from type 2 diabetes. Curr Hypertens Rep 2002; 4: 185-90.
97. Pisoni R, Ruggenenti P, Remuzzi G. Renoprotective therapy in patients with non-diabetic nephropathies. Drugs 2001; 61: 733-45.
98. Sasso FC, Carbonara O, Persico M, et al. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care 2002; 25: 1909-13.
99. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-8.
100. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870.
101. Rossing K, Christensen PK, Andersen S, Hovind P, Hansen HP, Parving HH. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study. Comparative effects of Irbesartan on ambulatory and office blood pressure: a substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study. Diabetes Care 2003; 26: 569-74.
102. Andersen S, Brochner-Mortensen J, Parving HH. Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 2003; 26: 3296-302.
103. American Diabetes Association. Diabetic nephropathy. Diabetes Care 2003; 26: 894-8.
104. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.
105. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003; 26: 2268-74.
106. Guidelines Committee. 2003. European Society of Hypertension - European Society of Cardiology Guidelines or the management of arterial hypertension. J Hypertens 2003; 21: 1011-59.
107. Volpe M, Cosentino F, Ruilope LM. Is it time to measure microalbuminuria in hypertension? J Hypertens 2003; 31: 1213-20.
108. Diercks GF, Janssen WM, van Boven AJ, et al. Rationale, design, and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive, nonhypercholesterolemic subjects with microalbuminuria (the Prevention of REnal and Vascular ENdstage Disease Intervention Trial [PREVEND IT]). Am J Cardiol 2000; 86: 635-8.
109. Asselbergs FW, Diercks GFH, Hillege HL, et al on behalf of the PREVEND IT Investigators. Effects of fosinopril and pravastatin on cardiovascular events in microalbuminuric subjects without hypertension and hypercholesterolemia: a single-center, double-blind, randomized, placebo-controlled trial with 2 × 2 factorial design (PREVEND IT) (Late-Breaking Clinical Trial Abstract). Circulation 2003; 108: P4.
110. Donnelly R, Rea R. Microalbuminuria: how informative and reliable are individual measurements? J Hypertens 2003; 21: 1229-33.